Status:
UNKNOWN
The Value of circRNAs (hsa_circ_0004001) in Early Diagnosis of HCC
Lead Sponsor:
Assiut University
Conditions:
Hepatic Cell Carcinoma
Eligibility:
All Genders
18-80 years
Brief Summary
1. To evaluate the clinical utility of plasma circRNAs (hsa\_circ\_0004001) as a non invasive diagnostic biomarker for HCC patients and to differentiate between malignant and nonmalignant hepatic diso...
Detailed Description
Hepatocellular carcinoma (HCC) is one of the most common malignant gastrointestinal tumours worldwide and is characterized by high morbidity and mortality rates . HCC is the sixth common cancer and th...
Eligibility Criteria
Inclusion
- group one patients early diagnosed as HCC
- group two patient diagnosed with chronic non-malignant liver disease 3 group three healthy control group
Exclusion
- Patients with any other type of malignant or benign tumors should be excluded from our study.
- History of chemotherapy or surgical treatment of cancer
Key Trial Info
Start Date :
November 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2025
Estimated Enrollment :
102 Patients enrolled
Trial Details
Trial ID
NCT06042842
Start Date
November 1 2023
End Date
February 1 2025
Last Update
October 4 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.